53
Participants
Start Date
October 12, 2021
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
Sacituzumab Govitecan-hziy
Administered intravenously
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing
Chinese Academy of Medical Sciences Cancer Hospital, Beijing
Beijing Cancer Hospital, Beijing
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Jiangsu Province Hospital, Nanjing
Anhui Provincial Hospital, Hefei
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Fujian Cancer Hospital, Fuzhou
Henan Cancer Hospital, Zhengzhou
The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou
Lead Sponsor
Gilead Sciences
INDUSTRY